Literature DB >> 15680267

The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.

Adriana Georgescu1, Florentina Pluteanu, Maria-Luisa Flonta, Elisabeta Badila, Maria Dorobantu, Doina Popov.   

Abstract

Nebivolol is known as a highly selective beta1-adrenoceptor antagonist. Based on the reported vasodilator effect of nebivolol, we examined the cellular mechanisms by which the drug induces renal artery vasodilation, an issue of potential relevance for condition associated with high blood pressure. To this purpose, myograph and patch-clamp techniques were used. Small mouse renal arteries were placed in the myograph chamber, and after the optimal concentration for the vasodilator effect of nebivolol was established (50 microM), the arteries were further investigated to assess the potential contribution of nitric oxide (NO) and of Ca2+ ions to the nebivolol-induced effect, by exposing the arteries to the specific inhibitors such as N(G)-nitro-L-arginine methylester (L-NAME, 100 microM), ethylenglycol-bis-(beta-amino-ethylen ester) N,N'-tetraacetic acid (EGTA, 4 microM) and thapsigargin (1 microM). The expression of NO synthase was evaluated by the Western-blot technique. Using myograph and patch-clamp techniques applied on intact renal artery, we investigated the role of beta2-adrenoceptors, of myoendothelial junctions and of Ca(2+)-activated K+ channels in the vasodilatory effects of nebivolol, using 100 microM butoxamine, 40 microM 18 beta-glycyrrhetinic acid, 1 mM tetraethylammonium, and 100 nM iberiotoxin, respectively. The results showed that the cellular mechanisms of the vasodilator effect of nebivolol on the renal artery entail (i) activation of the endothelial beta2-adrenoceptor, (ii) participation of [Ca2+]i, (iii) increase in NO and eNOS, and (iv) activation of Ca(2+)-activated K+ channels. The cellular mechanisms underlying vasodilator effect of nebivolol on the artery explain the favorable effect of this drug in hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15680267     DOI: 10.1016/j.ejphar.2004.11.043

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.

Authors:  Jennifer M Sasser; Natasha C Moningka; Tatsiana Tsarova; Chris Baylis
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

2.  Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries.

Authors:  Ana M Briones; Craig J Daly; Francesc Jimenez-Altayo; Sonia Martinez-Revelles; Jose M Gonzalez; John C McGrath; Elisabet Vila
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario
Journal:  Am J Nephrol       Date:  2010-11-02       Impact factor: 3.754

4.  Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats.

Authors:  Javad Habibi; Melvin R Hayden; James R Sowers; Lakshmi Pulakat; Roger D Tilmon; Camila Manrique; Guido Lastra; Vincent G Demarco; Adam Whaley-Connell
Journal:  Endocrinology       Date:  2010-12-22       Impact factor: 4.736

5.  Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats.

Authors:  Melvin R Hayden; Javad Habibi; Adam Whaley-Connell; Dilek Sowers; Megan Johnson; Roger Tilmon; Deepika Jain; Carlos Ferrario; James R Sowers
Journal:  Am J Nephrol       Date:  2010-01-25       Impact factor: 3.754

6.  Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation.

Authors:  Juan P Aragón; Marah E Condit; Shashi Bhushan; Benjamin L Predmore; Sandeep S Patel; D Bennett Grinsfelder; Susheel Gundewar; Saurabh Jha; John W Calvert; Lili A Barouch; Madhav Lavu; Harold M Wright; David J Lefer
Journal:  J Am Coll Cardiol       Date:  2011-12-13       Impact factor: 24.094

7.  Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Javad Habibi; Megan Johnson; Roger Tilmon; Nathan Rehmer; Jenna Rehmer; Charles Wiedmeyer; Carlos M Ferrario; James R Sowers
Journal:  Am J Nephrol       Date:  2009-07-17       Impact factor: 3.754

8.  Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta.

Authors:  T Tran Quang; B Rozec; L Audigane; C Gauthier
Journal:  Br J Pharmacol       Date:  2009-02-04       Impact factor: 8.739

9.  Nebivolol/Hydrochlorothiazide : a new fixed-dose combination for effective simplified antihypertensive therapy.

Authors:  Ettore Malacco
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

10.  Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial.

Authors:  Alain Cohen-Solal; Dipak Kotecha; Dirk J van Veldhuisen; Daphne Babalis; Michael Böhm; Andrew J Coats; Michael Roughton; Philip Poole-Wilson; Luigi Tavazzi; Marcus Flather
Journal:  Eur J Heart Fail       Date:  2009-08-01       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.